Abby Hardy, Author at BioTuesdays

Developments

aTyr Pharma doses first patient in Phase 2 COVID-19 trial

aTyr Pharma (NASDAQ:LIFE) dosed the first patient in a Phase 2 study evaluating ATYR1923, an immunomodulator, in COVID-19 patients with severe respiratory complications. The study will enroll 30 COVID-19-positive...

June 15, 2020

Developments

X4 Pharma reports positive Phase 2 mavorixafor data in WHIM syndrome

X4 Pharmaceuticals (NASDAQ:XFOR) reported positive results from its ongoing Phase 2 trial of mavorixafor for WHIM syndrome. WHIM stands for warts; hypogammaglobulinemia, or low antibody levels; infections; and...

June 12, 2020

Developments

Leap Therapeutics DKN-01 gets FDA orphan drug designation for gastric and gastroesophageal junction cancer

The FDA granted Leap Therapeutics’ (NASDAQ:LPTX) DKN-01 orphan drug designation for the treatment of gastric and gastroesophageal junction cancer. DKN-01 is a humanized monoclonal antibody that targets the Dickkopf-1...

June 12, 2020

Developments

Aprea Therapeutics updates Phase 1b/2 eprenetapopt trial results

Aprea Therapeutics (NASDAQ:APRE) reported updated data from its Phase 1b/2 trial evaluating eprenetapopt, in combination with azacytidine, for the treatment of myelodysplastic syndromes (MDS) and acute myeloidleukemia...

June 12, 2020

Executive Moves

Hepion names drug development expert, Dr. Peter Wijngaard, to its board

Peter Wijngaard Hepion Pharmaceuticals (NASDAQ:HEPA) appointed industry veteran, Dr. Peter Wijngaard, to its board of directors. “Dr. Wijngaard provided invaluable guidance to Hepion’s management team during our earlier...

June 10, 2020

Developments

Karyopharm Therapeutics doses first glioblastoma patient in Phase 1/2 selinexor study

Karyopharm Therapeutics (NASDAQ:KPTI) dosed the first patient in a Phase 1/2 clinical study evaluating oral selinexor in patients with newly diagnosed or recurrent glioblastoma (GBM). This global study is expected to...

June 9, 2020

Developments

MD Anderson resumes Phase 1b trial of Soricimed’s SOR-C13

Closely-held Soricimed Biopharma reported that the MD Anderson Cancer Center has resumed its investigator-initiated trial of Soricimed’s SOR-C13. MD Anderson completed the first cohort of the dose escalation phase of...

June 9, 2020

Developments

MacroGenics margetuximab gets FDA orphan drug designation for gastric cancer

MacroGenics’ (NASDAQ:MGNX) margetuximab received FDA orphan drug designation for the treatment of gastric and gastroesophageal junction cancer. Margetuximab is currently being evaluated in a Phase 2/3 trial in...

June 5, 2020

Developments

Tenax posts positive Phase 2 levosimendan data

Tenax Therapeutics (NASDAQ:TENX) reported positive results from a Phase 2 trial evaluating levosimendan for the treatment of patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH...

June 4, 2020

Developments

Idera Pharma reports positive initial Phase 2 data of tilsotolimod in colorectal cancer

Idera Pharma (NASDAQ:IDRA) reported positive preliminary data from its Phase 2 trial of tilsotolimod, in combination with Opdivo and Yervoy, in immunotherapy-naive micro-satellite stable colorectal cancer (MSS-CRC)...

June 4, 2020

Author - Abby Hardy

aTyr Pharma doses first patient in Phase 2 COVID-19 trial

X4 Pharma reports positive Phase 2 mavorixafor data in WHIM syndrome

Leap Therapeutics DKN-01 gets FDA orphan drug designation for gastric and gastroesophageal junction cancer

Aprea Therapeutics updates Phase 1b/2 eprenetapopt trial results

Hepion names drug development expert, Dr. Peter Wijngaard, to its board

Karyopharm Therapeutics doses first glioblastoma patient in Phase 1/2 selinexor study

MD Anderson resumes Phase 1b trial of Soricimed’s SOR-C13

MacroGenics margetuximab gets FDA orphan drug designation for gastric cancer

Tenax posts positive Phase 2 levosimendan data

Idera Pharma reports positive initial Phase 2 data of tilsotolimod in colorectal cancer

Subscribe